University of California

Dartmouth College

University of Massachusetts

Chiba University

Burnham Institute for Medical Research

Eicosis, LLC

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States Government As Represented by the Department of Veterans Affairs

Beth Israel Deaconess Medical Center, Inc.

Massachusetts Eye and Ear Infirmary

Sanford-burnham Medical Research Institute

Goethe-university Frankfurt

Hammock, Bruce D.

Lee, Kin Sing Stephen

Bruce D Hammock

Christophe H Morisseau

Sung Hee Hwang

Jiang Zheng

Ahmet Bora Inceoglu

Paul Daniel Jones

John Newman

David F Grant

In-Hae Kim

Takaho Watanabe

Nipavan Chiamvimonvat

Susumu Maeda

Qihong Huang

John C Reed

Billy Fred McCutchen

Quinn L Deveraux

Kenji Hashimoto

Huazhang Huang

Horacio Kido

Dean R Madden

Babak Borhan

Alyson E Mitchell

Kin Sing Lee

Guodong Zhang

Hsing-Ju Tsai

Karen Wagner

Richard Gless, Jr

Jessica F Greene

Marlene F Sisemore

A Daniel Jones

Hiroko Maeda, Legal Representative

Mehran F Moghaddam

Bryony C Bonning

Deanna Kroetz

Terry Nelson Hanzlik

Darryl C Zeldin

James Sanborn

Jun Yang

Sean Kodani

Bora Inceoglu

Rong Zhang

Guomin Shan

Aaron Wecksler

Angel Maquieira

James Fergusson

Jeffrey M Cheek

Kazuhiko Matoba

Rafael Herrmann

Kin Sing Stephen Lee

Haim Moskowitz

Natalia Vasylieva

Vernon K Ward

Lawrence G Harshman

Jiexian Dong

Weicang Wang

Vikas P Sukhatme

Paul Henderson

Chong-Xian Pan

Rama M Belagaje

Hongyong Zhang

Kip M Connor

Paul Whetstone

Maike Zimmermann

Fawaz G Haj

Ahmed Bettaieb

Ralph William De Vere White

Dipak Panigrahy

Kelli Hoover

Lucia Vanrell

Ai-Hong Ma

Gabriel Lassabe

Fuli Wang

Rene Bloecher

Yang Kevin Xiang

Todd Harris

Raghavender Reddy Gopireddy

Eugen Proschak

Shirley Gee

Tristan Rose

Gabriela Zurek

Elizabeth Fowler

Eliahu Zlotkin

Padmini Sirish

Eiichi Hasegawa

Kazuhiko Motoba

Marvin H Goodrow

Tonya Severson

Matthew L Philpott

Jeffrey K Beetham

Susan E Bennett

Linda M Reilly

Ferenc Szurdoki

Seung-Jin Ma

Robert H Weiss

Hiromi Inoue Wettersten

Judith S Stern

Alonso G P Guedes

Steven L Jinks

Christopher D Bahl

Gualberto Gonzalez-Sapienza

The invention provides methods for treating, suppressing, or preventing detrimental cytokine and/or lipid mediator surges that can result from a variety of different diseases, conditions, and therapeutic treatments, e.g., by inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH).

Methods for the prevention or treatment of cytokine storm

Provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting, treating and/or reversing a neurodevelopmental disorder related to prenatal maternal immune activation in an individual in need thereof comprising administering to said individual an agent that increases the level of epoxy-fatty acids wherein said individual experienced maternal immune activation one or more times during gestation. Also provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting treating and/or reversing schizophrenia or autism spectrum disorder an individual comprising administering to said individual an agent that increases the level of epoxy-fatty acids.

Treatment of neurodevelopmental disorders

Provided are methods of preventing, delaying, mitigating, reducing and/or inhibiting alpha-synuclein aggregates in the brains of a subject at risk of developing or suffering a cognitive disease associated with, caused and/or mediated at least in part by alpha-synuclein aggregates, for example, Parkinson's Disease or Dementia with Lewy Bodies (DLB).

Methods of inhibiting formation of alpha synuclein aggregates

Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment ofinfection.

Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

The present disclosure provides compounds for the inhibition of soluble epoxide hydrolase and associate disease conditions, as well as a method of treating or preventing disorders in a subject by inhibition of soluble epoxide hydrolase.

Co-crystal of sorafenib derivatives and process for preparation thereof

The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH)

Provided are methods for improving the efficacy and success of cell-based therapies by administration of stem cells which have been preconditioned with an inhibitor of soluble epoxide hydrolase (sEHI), as well as kits, stents and patches for administering sEHI-preconditioned stem cells, as sole active agent or in combination with an agent that increases the production and or levels of EETs.

Methods of improving cell-based therapy

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

Provided herein are novel bioavailable dual inhibitors capable of inhibiting both soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4), and methods of using the same.

Orally available sEH/PDE4 dual inhibitors

Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase ('COX')-1, COX-2, and 5-lipoxygenase ('5-LOX'). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.

Methods of improving cancer chemotherapy

This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

Methods of treating mental disorders

The present invention provides a synthetic chemical method for preparing &#x3c9;-hydroxylated polyunsaturated fatty acids (PUFAs) including 20-hydroxyeicosatetraenoic acid (20-HETE), 20-hydroxyeicosapentaenoic acid (20-HEPE), and 22-hydroxydocosahexaenoic acid (22-HDoHE) and a method of use thereof for treating cancer and macular degeneration.

Synthesis and use of &#x3c9;-hydroxylated polyunsaturated fatty acids

Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH)

Provided are methods and compositions for preventing, reducing, mitigating and treating pain, particularly neuropathic pain by the combined administration of an agent that increases EETs and an agent that reduces/inhibits endoplasmic reticulum (ER) stress.

Methods of inhibiting pain

Growing community of inventors

Davis, CA, United States of America

Bruce D Hammock